NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma Article

Gilbert, Mark R, Pugh, Stephanie L, Aldape, Ken et al. (2017). NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma . JOURNAL OF NEURO-ONCOLOGY, 131(1), 193-199. 10.1007/s11060-016-2288-5

Open Access International Collaboration

cited authors

  • Gilbert, Mark R; Pugh, Stephanie L; Aldape, Ken; Sorensen, A Gregory; Mikkelsen, Tom; Penas-Prado, Marta; Bokstein, Felix; Kwok, Young; Lee, R Jeffrey; Mehta, Minesh

sustainable development goals

authors

publication date

  • January 1, 2017

webpage

published in

keywords

  • Anti-angiogenic treatment
  • CRITERIA
  • Clinical Neurology
  • Combination therapy
  • GLIOMAS
  • Glioblastoma
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Randomized trial
  • SINGLE-AGENT BEVACIZUMAB
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 193

end page

  • 199

volume

  • 131

issue

  • 1